Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionPrincipal Financial Group Inc
Latest Disclosed Ownership5,649 shares
Latest Disclosed Value $ 1,869,085
Principal Financial Group Inc reports 61.49% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 4, 2026 - Principal Financial Group Inc filed a 13F-HR form disclosing ownership of 5,649 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $1,613,919 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 2, 2026 disclosing 3,498 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 61.49% during the quarter. The current value of the position is $1,471,564 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-04 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,649 2,151 61.49 1,869 34.46 0.0005
2026-02-02 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,498 -1,922 -35.46 1,391 -43.75 0.0007
2025-11-04 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,420 -45,114 -89.27 2,472 -85.00 0.0012
2025-08-08 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 50,534 15,833 45.63 16,479 75.88 0.0087
2025-04-28 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 34,701 24,323 234.37 9,370 283.66 0.0053
2025-01-31 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,378 -230 -2.17 2,442 -16.28 0.0013
2024-10-31 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,608 -3,581 -25.24 2,918 -15.38 0.0016
2024-07-29 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,189 -5,167 -26.69 3,448 19.19 0.0020
2024-04-29 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 19,356 -273 -1.39 2,893 -23.02 0.0017
2024-02-07 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 19,629 -2,876 -12.78 3,757 -5.72 0.0024
2023-11-02 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 22,505 843 3.89 3,986 -3.14 0.0029
2023-08-07 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 21,662 678 3.23 4,114 -2.12 0.0028
2023-05-09 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,984 -2,979 -12.43 4,204 -26.19 0.0030
2023-02-09 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 23,963 -2,482 -9.39 5,695 7.58 0.0043
2022-11-09 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 26,445 -5,083 -16.12 5,293 15.12 0.0042
2022-08-10 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 31,528 3,063 10.76 4,598 -1.08 0.0034
2022-05-09 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 28,465 -1,557 -5.19 4,648 -8.72 0.0018
2022-05-09 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,881 1,940
2022-02-09 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30,022 -8,618 -22.30 5,092 -30.21 0.0030
2021-11-09 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 38,640 -4,295 -10.00 7,296 0.25 0.0048
2021-08-10 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 42,935 2,855 7.12 7,278 28.61 0.0047
2021-05-10 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 40,080 2,014 5.29 5,659 14.39 0.0040
2021-02-23 2020-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 38,066 4,901 14.78 4,947 2.46 0.0037
2021-02-08 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 38,066 4,901 4,947 1,946.2260
2020-11-06 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 33,165 -3,026 -8.36 4,828 -9.93 0.0041
2020-08-05 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 36,191 7,274 25.15 5,360 70.32 0.0048
2020-05-12 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 28,917 1,478 5.39 3,147 -0.41 0.0035
2020-02-05 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,439 -93 -0.34 3,160 42.73 0.0026
2019-11-13 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,532 -1,035 -3.62 2,214 6.80 0.0020
2019-08-12 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 28,567 2,934 11.45 2,073 -13.48 0.0019
2019-05-10 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,633 1,788 7.50 2,396 37.78 0.0022
2019-02-14 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 23,845 -1,337 -5.31 1,739 -21.10 0.0019
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,182 893 3.68 2,204 -7.86 0.0019
2018-08-13 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 24,289 -236 -0.96 2,392 -18.11 0.0022
2018-05-14 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 24,525 1,263 5.43 2,921 -1.15 0.0028
2018-02-12 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 23,262 10,063 76.24 2,955 90.52 0.0027
2017-11-02 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,199 -2,057 -13.48 1,551 27.44 0.0015
2017-08-08 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,256 2,928 23.75 1,217 92.56 0.0012
2017-05-11 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,328 -523 -4.07 632 31.39 0.0008
2017-02-13 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,851 -2,266 -14.99 481 -53.07 0.0006
2016-11-10 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,117 -35 -0.23 1,025 21.88 0.0014
2016-08-09 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,152 1,761 13.15 841 0.00 0.0012
2016-05-10 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,391 -77 -0.57 841 -33.68 0.0012
2016-02-09 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,468 21 0.16 1,268 17.30 0.0019
2015-11-12 2015-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 13,447 5,998 80.52 1,081 21.05 0.0017
2015-11-09 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,447 1,081
2015-08-10 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,449 2,952 65.64 893 90.00 0.0013
2015-05-14 2015-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 4,497 -721 -13.82 470 -7.11 0.0007
2015-05-12 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,497 470
2015-02-12 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,218 5,218 0.00 506 0.0008
2014-11-13 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -30,604 -100.00 0 -100.00
2014-08-12 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 30,604 -45,820 -59.95 1,933 -62.33 0.0033
2014-05-13 2014-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 76,424 -176 -0.23 5,132 4.14 0.0092
2014-02-12 2013-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 76,600 4,252 5.88 4,928 6.39 0.0092
2013-11-05 2013-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 72,348 55,353 325.70 4,632 778.94 0.0096
2013-08-12 2013-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,995 16,995 527 0.0012
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.